ANI Pharmaceuticals, Inc. (ANIP) Financials
ANIP Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 1.4 billion | 859.7 million |
| Dec. 31, 2025 | 1.4 billion | 899.7 million |
| Sept. 30, 2025 | 1.4 billion | 902.3 million |
| June 30, 2025 | 1.3 billion | 881.4 million |
ANIP Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | 52.3 million | 10.2 million |
| Dec. 31, 2025 | 6.5 million | 9.8 million |
| Sept. 30, 2025 | 37.9 million | 9.7 million |
| June 30, 2025 | 68.9 million | 9.6 million |
ANIP Net Income
No data available :(
ANIP Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 311.2 million | 308.5 million | - |
| Dec. 31, 2025 | 285.6 million | 307.9 million | - |
| Sept. 30, 2025 | 262.6 million | 307.4 million | - |
| June 30, 2025 | 223.5 million | 608.3 million | - |
ANIP Shares Outstanding
ANIP Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 6.1 million | 10.6 million | 73.7 million | - |
| Dec. 31, 2025 | 23.9 million | 12.3 million | 82.8 million | - |
| Sept. 30, 2025 | 6.2 million | 12.3 million | 76.7 million | - |
| June 30, 2025 | 6.9 million | 16.5 million | 81.8 million | - |
ANIP Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 237.5 million | 114.5 million |
| Dec. 31, 2025 | 247.1 million | 9.5 million |
| Sept. 30, 2025 | 227.8 million | 116.0 million |
| June 30, 2025 | 211.4 million | 74.6 million |
ANIP Revenue by Segment
Graph available only for paid members. Upgrade to see it.
ANIP
Price: $79.59
52 week price:
Payout Ratio Range:
Earnings Per Share: 3.91 USD
P/E Ratio: 20.35
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Volume: 67658
Ebitda: 16.4 millionMarket Capitalization: 1.8 billion